References
- 1. Lindsey, P. A., Nyirenda, V. R., Barnes, J. I., Becker, M. S., McRobb, R., Tambling, C. J., et al., 2014: Underperformance of African protected area networks and the case for new conservation models: insights from Zambia. Plos One, 9, 5, e94109. DOI: 10.1371/journal.pone.0094109
- 2. IARC, 2004: Tobacco smoke and involuntary smoking. Monographs on the Evaluation of Carcinogenic Risk to Humans, 83, 33–1187.
- 3. Collin, G., H ö ke, H., Talbiersky, J., 2006: Anthracene. In Ullmann ’ s Encyclopedia of Industrial Chemistry, Wiley-VCH, Weinheim. DOI: 10.1002/14356007.a02_343. pub2
- 4. Verschueren, K., Marcoen, A., Schoefs, V., 1996: The internal working model of the self, attachment, and competence in five-year-olds. Child Dev., 67, 5, 2493–2511.DOI: 10.2307/1131636
- 5. Rao, P-S. 2014: Anthracene. In Encyclopaedia of Toxicology, 3rd ed., pp. 260–261.
- 6. Abdul Lateef, E. N., Hussein, M. A., Mustafa, S. R., Taen, M. M., Ali, S. A., Saheab, N., 2021: Toxicity of anthracene on the function of the liver and kidney of the common carp cypricus carpio. Egyptian J. Aquat. Biol. Fish, 25, 3, 3, 831–840. DOI: 10.21608/EJABF.2021.182302
- 7. Dey, S., Samanta, P., Mondal, N. S., Kole, D., Mandal, A., Patra, A., Ghosh, A. R., 2019: Dose specific responses of Anabas testudineus (Bloch) to anthracene (PAH): haemato-logical and biochemical manifestation. Emerg. Contamin., 5, 232–239. DOI: 10.1016/j.emcon.2019.07.001
- 8. Palanikumar, L., Kumaraguru, A. K., Ramakritinan, C. M., Anand, M., 2012: Biochemical response of anthracene and benzo[a]pyrene to milkfish Chanos chanos. Ecotoxicol. Environ. Saf., 75, 1, 187–197. DOI: 10.1016/j. ecoenv.2011.08.028
- 9. Saganuwan, S. A., Orinya, O. A. 2016: Toxico-neurological effects of piroxicam in monogastric animals. J. Exp. Neurosci., 10, 121–128. DOI: 10.4137/JEn.s40144
- 10. Saganuwan, S. A., Onyeyili, P. A., 2016: The paradox of human equivalent dose formula: a canonical case study of Abrus precatorius aqueous leaf extract in monogastric animals. Mac. Vet. Rev., 39, 1, 23–32. DOI: 10.1515/macvetrev-2015-0061
- 11. Akogwu, E. I., Saganuwan, S. A., Onyeyili, P. A., 2017: Comparative pharmacokinetics of piroxicam in male and female west African dwarf goats. Cog. Food Agric., 3, 1–8. DO I: 10.1080/23311932.2017.1294444
- 12. Oluchi, O. M., Chukwuebuka, N. H., Orbunde, D. K., Daniel, W. A., Aondohemba, U.V., Ieren, I. I., et al., 2024: Evaluation of Benz[a]anthracene-induced pulmonary toxicity in Rattus norvegicus. J. Toxicity Envir. Health Sci., 16, 1, 1–12. DOI: 10.5897/JTEHS2023.0517
- 13. Thermo Fisher Scientific, 2024: Carboplatin In: Safety Data Sheet, Health, Safety and Environment Department. pp. 1–8.
- 14. Saganuwan, S. A., 2019: Effects of therapeutic and toxic agents on erythrocytes of different species of animals. In Erythrocytes, Intech Open, London, pp. 176. DOI: 10.5772/intechopen.85865
- 15. Uzoamaka, A. M., Saganuwan, S. A., Ahur, M. V., Akande, T. 2025: Ameliorative effects of piroxicam on anthracene-induced lung toxicity in female Rattus norvegicus. Folia Vet., 69, 4, 49–63. DOI: 10.2478/fv-2025-0036
- 16. Saganuwan, S. A., 2012: Principle of pharmacological calculations 1st ed; Ahmadu Bello University press, pp. 528.
- 17. Kisani, A. I., Immaculate, A. N., Saganuwan, S. A., 2022: Comparative local anaesthetic effect of lignocaine, ligno-caine-adrenaline and water extracts of Annona muricata during castration in dogs. Adv. Trad. Med. 23, 851–861. DOI: 10.1007/s13596-022-00655-1
- 18. Saganuwan, S. A., Onyeyili, P. A., 2012: Haematonic and plasma expander effects of aqueous leaf extract of Abrus precalorius in Mus musculus. Comp. Clin. Pathol., 21, 1249–1255. DOI: 10.1007/s00580-011-1274-8
- 19. Brown, B. A., 1976: Haematology principles and procedures, 2nd ed. Lea and Fabiger, Philadelphia, pp. 56–81.
- 20. Cheesebrough, M., 2005: Examination of blood for malaria parasite. District Laboratory practice in tropical countries. Part 1. Cambridge University Press, Cambridge, pp. 434.
- 21. Talke, H., Schubert, G. E., 1965: Enzymatic urea determination in the blood and serum in the Warburg optical test. Klin. Wohcenschr., 43, 174–175.
- 22. Blass, K. G., Thibert, R. J., Lam, L. K., 1974: A study of mechanism of Jaff é reaction. Clin. Chem., 12, 7, 336–343. DOI: 10.1515/cclm.1974.12.7.336
- 23. Saganuwan, S. A., 2018: The use of body surface area for determination of age, body weight, urine creatinine, plasma creatinine, serum creatinine, urine volume and creatinine clearance: the reliable canonical method for accessing renotoxicity in animals. Comp. Clin. Pathol., 27, 1531–1536. DOI: 10.1007/s00580-018-2769-3
- 24. Bergemeyer, H. U., Bowers Jr., G. N., Horder, M., Moss, D. W., 1976: Provisional recommendations on IFCC methods for the measurement of catalytic concentrations of enzymes. Part 2. IFCC method for aspartate aminotransferase. Clin. Chim. Acta, 70, 2, 19–29. PMID: 954207
- 25. Henley, K. S., 1980: IFCC method for alanine aminotransferase. Clin. Chim. Acta, 105, 1, 155–166. DOI: 10.1016/0009-8981(80)90106-0
- 26. Roy, A. V., 1970: Rapid method for determining alkaline phosphatase activity in serum with thymolphthalein mono-phosphate. Clin. Chem., 16, 5, 431–436. PMID: 5443769
- 27. Williams, A. L. B. and Hoofnagle, J. H., 1988: Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis relationship to cirrhosis. Gastroenterol., 95, 3, 734–739. DOI: 10.1016/s0016-5085(88)80022-2
- 28. Daniel, W. W., 2010: Biostatistics: Basic Concept and Methodology for Health Sciences, 9th ed., Wiley, New Delhi, pp. 783.
- 29. Zahorec, R., 2021: Neutrophil to lymphocyte ratio, past, present and future perspectives. Bratisl. Med. J., 122, 7, 474–488. DOI: 10.4149/BLL_2021_078
- 30. Cohen, J. A., Kaplan, M. M., 1979: The SGOT/SGPT ratio–an indicator of alcoholic liver disease. Dig. Dis. Sci., 24, 11, 835–838. DOI: 10.1007/BF01324898
- 31. Saganuwan, S. A., 2023: Ameliorative effects of piroxicam on perchloric acid-induced thyroid gland hormones disruption in male rats. J. King Saud Univ-Sci., 35, 5, 102661. DOI: 10.1016/j.jksus.2023.102661
- 32. Roeland, E. J., Fintelmann, F. J., Hilton, F., Yang, R., Whalen, E., Tarasenko, L., et al., 2024: The relationship between weight gain during chemotherapy and outcomes in patients with advanced non-small cell lung cancer. J. Cachexia Sarcopenia Muscle, 15, 3, 1030–1040. DOI: 10.1002/jcsm.13426
- 33. Story, A. L., Boston, S. E., Kilkenny, J. J., Singh, A., Woods, J. P., Culp, W. T. N., et al., 2017: Evaluation of weight change during carboplatin therapy in dogs with appendicular osteosarcoma. J. Vet. Intern. Med., 31, 4, 1159–1162. DOI: 10.1111/jvim.14724
- 34. Cheng, Y.-J., Wu, R., Cheng, M.-L., Du, J., Hu, X.-W., Yu, L., et al., 2017: Carboplatin-induced hematotoxicity among patients with non-small cell lung cancer: Analysis on clinical adverse events and drug-gene interactions. Oncotarget, 8, 19, 32228–32236. DOI: 10.18632/oncotarget.12951
- 35. Kasuga, I., Makino, S., Kiyokawa, H., Katoh, H., Ebihara, Y., Ohyashiki, K., 2001: Tumor-related leukocytosis as linked with poor prognosis in patient with lung carcinoma. Cancer, 92, 9, 2399–2405. DOI: 10.1002/1097-0142(20011101)92:9<;2399::aid-cncr1588>3.0.co;2-w
- 36. Sprague, B. L., Trentham-Dietz, A., Klein, B. E. K., Klein, R., Cruickshanks, K. J., Lee, K. E., Hampton, J. M., 2008: Physical activity, white blood cell count, and lung cancer risk in a prospective cohort study. Cancer Epidemiol. Biomarkers Prev., 17, 10, 2714–2722. DOI: 10.1158/1055-9965.EPI-08-0042
- 37. Wong, J. Y. Y., Bassig, B. A., Loftfield, E., Hu, W., Freedman, N. D., Ji, B., et al., 2020: White blood cell count and risk of incident lung cancer in the UK Biobank. JNCI Cancer Spect., 4, 2, 1–9. DOI: 10.1093/jncics/pkz102
- 38. Uribe – Querol, E., Rosales, C., 2015: Neutrophils in cancer: two sides of the same coin. J. Immunol. Res., 1, 983698, 1–21. DOI: 10.1155/2015/983698
- 39. Kohutek, F., Bystricky, B., 2019: Leukocytosis as a negative prognostic factor in patients with lung cancer: Which subpopulation of leucocytes is responsible? Tumor Biol. Pathol., 30, 5, 799.
- 40. Saganuwan, S.A., 2016: Physicochemical and structure-activity properties of piroxicam—a mini review. Comp Clin Pathol., 25, 941–945. DOI: 10.1007/s00580-016-2284-3
- 41. Young, B., Stewart, W., O ’ Dowd, G., 2011: Wheater’s basic pathology: a text, atlas and review of histopathology. 15th ed. International edition. pp. 174–175.
- 42. Campbell, M.S., Makar, G.A., 2005: Safety of short-term administration of celecoxib in decompensated cirrhosis. Hepatol., 42, 1, 238. DOI: 10.1002/hep.20744
- 43. Aloe, C., Wang, H., Vlahos, R., Irving, L., Steinfort, D., Bozinovski, S., 2021: Emerging and multifaceted role of neutrophils in lung cancer. Transl. Lung Cancer Res., 10, 6, 2806–2818. DOI: 10.21037/tlcr-20-760
- 44. Wang, Z., Chen, B., Fu, Y., Ou, C., Rong, Q., Kong, X., et al., 2022: Eosinophilia and Lung Cancer: Analysis from Real-World Data and Mendelian Randomization Study. Front. Med. (Lausanne), 9, 830754. DOI: 10.3389/fmed.2022.830754
- 45. Anthony, H. M., 1982: Blood basophils in lung cancer. Br. J. Cancer, 45, 2, 209–216. DOI: 10.1038/bjc.1982.35
- 46. Ahur, V. M., Agada, P. O., Saganuwan, S. A., 2012: Estimating the plasma and serum activity levels of aspartate aminotransferase and alanine aminotransferase, in live animals using regression model. Trends Appl. Sci. Res., 7, 9, 748–757. DOI: 10.3923/tasr.2012.748.757
- 47. Saganuwan, S. A., 2017: Functional chemical groups that may likely become a source for the synthesis of novel central nervous system (cns) acting drugs. Centr. Nerv. Syst. Agents Med. Chem., 17, 3, 178–186. DOI: 10.2174/187152491766 6170502153752
- 48. Saganuwan, S. A., 2017: Toxicity studies of drugs and chemicals in animals: an overview. Bulg. J. Vet. Med., 20, 4, 291–318. DOI: 10.15547/bjvm.983
- 49. Saganuwan, S. A., 2019: Chemistry and effects of brainstem acting drugs. Centr. Nerv. Syst. Agents Med. Chem., 19, 3, 180–186. DOI: 10.2174/1871524919666190620164355
- 50. Sedlack, A. J. H., Meyer, C., Mench, A., Winters, C., Barbon, D., Obrzut, S., Mallak, N., 2024: Essentials of theranostics: A guide for physicians and medical physicists. Radiographics, 44, 1, e230097. DOI: 10.1148/rg.230097
- 51. Pradhan, S., Sonkar, C. K., 2023: Theranostic in nuclear medicine: Therapy to impact patient management and secure the future in the era of precision oncology. Oncol. Radiother. 17, 12, 756–763.
- 52. Awuah, W. A., Ahluwalia, A., Tan, J. K., Sanker, V., Roy, S., Ben-Jaafar, A., et al., 2025: Theranostics advances in the treatment and diagnosis of neurological and neurosurgical diseases. Arch. Med. Res., 56, 1, 103085. DOI: 10.1016/j. arcmed.2024.103085
- 53. Alexander, S. P. H., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., et al., 2023: The concise guide to pharmacology 2023/24: Introduction and other protein targets. Brit. J. Pharmacol., 180, S2, S1–S22. DOI: 10.1111/bph.16176
- 54. Ekhart, C., Rodenhuis, S., Schellens, J. H. M., Beijnen, J. H., Huitema, A. D. R., 2009: Carboplatin dosing in over-weight and obese patients with normal renal function, does weight matter? Cancer Chemother. Pharmacol. 64, 1, 115–122. DOI: 10.1007/s00280-008-0856-x
- 55. Saganuwan, S. A., 2017: In vivo piroxicam metabolites: Possible sources for synthesis of central nervous system acting depressants. Cent. Nerv. Syst. Agents Med. Chem., 17, 3, 172–177. DOI: 10.2174/1871524917666161111093759
- 56. Egbewale, S. O., Kumar, A., Mokoena, M. P., Olaniran, A. O., 2025: Optimization of anthracene biodegradation by indigenous Trichoderma lixii and Talaromyces pinophilus using response surface methodology. Ecotoxicol. Environ. Saf., 289, 117431. DOI: 10.1016/j.ecoenv.2024.117431
- 57. Schwenk, M. H., 2024: Carboplatin dosing on the basis of renal function: 30+ years after calvert. Kidney 360, 5, 2, 271–273. DOI: 10.34067/KID.0000000000000349
- 58. Chmielewski, P. P., Strzelec, B., Mozdziak, P., Kempisty, B., 2025: Neutrophil-to-lymphocyte ratio as a prognostic biomarker for long-term survival in older adults at a mental health care center: a historical cohort analysis. J. Clin. Med., 14, 7, 2509. DOI: 10.3390/jcm14072509
- 59. Xu, M., Yang, X., Zhang, J., Liu, D., Zhang, C., Wu, M., et al. 2024: The mechanism of anthracene degradation by trylophan-2,3-dioxygenase (T23D) in Comamonas testosteroni. Chem. Biol. Interact., 393, 110950. DOI: 10.1016/j. cbi.2024.110950
- 60. Omar, A. M., Abdulmalik, O., El-say, K.M., Ghatge, M. S., Cyril-Olutayo, M., Paredes, S., et al., 2023: Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities. Chem. Biol. Drug Des., 103, 1, e14371. DOI: 10.1111/cbdd.14371
- 61. Diaz-Uribe, C., Vallejo, W., Quinones, C., 2020: Physical-chemical study of anthracene selective oxidation by a Fe(III)- phenylporphyrin derivative. Int. J. Mol. Sci., 21, 1, 353. DOI: 10.3390/ijms21010353
- 62. Saganuwan, S. A, 2024: Structure-activity relationship of pharmacophores and toxicophores: the need for clinical strategy. Daru J. Pharm. Sci., 32, 2, 781–800. DOI: 10.1007/s40199-024-00525-y
- 63. Saganuwan, S. A, 2021: Application of modified Michaelis-Menten equations for determination of enzyme inducing and inhibiting drugs. BMC Pharmacol. Toxicol., 22, 57, 1–15. DOI: 10.1186/s40360-021-00521-x
- 64. de Sousa, G. F., Wlodarczyk, S.R., Monteiro, G., 2014: Carboplatin: Molecular mechanisms of action associated with chemoresistance. Braz. J. Pharm. Sci., 50, 4. 10.1590/S1984-82502014000400004
- 65. Kaushal, A., Verma, P., Singh, A. P., Singh, A. P., 2024: A critical review of piroxicam: From mechanism to adverse effects in clinical use. IJIRT, 11, 6, 3807–3811.
- 66. Mazumder, M. K., Borah, A., 2014: Piroxicam inhibits NMDA receptor-mediated excitotoxicity through allosteric inhibition of the GluN2B subunit: an in silico study elucidating a novel mechanism of action of the drug. Med. Hypotheses, 83, 6, 740–746. DOI: 10.1016/j.mehy.2014.09.031
- 67. Reitzer, L., 2004: Biosynthesis of glutamate, aspartate, asparagine, L-Alanine, and D-Alanine. EcoSal Plus, 1, 1, 26443364. DOI: 10.1128/ecosalplus.3.6.1.3